GlaxoSmithKline snaps up Boston Pharmaceutical's asset for up to $2 billion

Getting deals done in biopharmaceutical industry has been tough over the last few months but today FTSE 100-listed giant GlaxoSmithKline announced the $2 billion acquisition of Boston Pharmaceutical's lead asset, efimosfermin alfa.